The site provides a granular look at the firm's expanded technical infrastructure and its signature ModularCMC platform. This AI-enabled framework structures antibody development by combining standardized work packages with Quality-by-Design principles. By aligning these strategies with regulatory requirements, the platform aims to accelerate timelines for complex biologics, including multispecifics, Fc-fusion proteins, and antibody-drug conjugates.

Sheli Streck, Chief Commercial Officer at Wheeler Bio, noted that the digital update was necessary to accurately communicate the breadth of the firm's scientific capacity. Beyond technical specs, the platform emphasizes the company’s high-touch project management style, characterized by transparent communication and direct access to scientific leadership. The revamped portal also serves as a resource for biotechnology developers to evaluate manufacturing options and explore the company’s evolving partner network.